このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

頭頸部がんに対する通常の化学療法および放射線療法への M6620 (VX-970、ベルゾセルチブ) の追加のテスト

2026年11月14日 更新者:National Cancer Institute (NCI)

局所進行頭頸部扁平上皮癌患者(HNSCC; SDC 10060121)におけるシスプラチンおよびXRTと組み合わせたM6620(VX-970、ベルゾセルチブ)の第I相試験

This phase I trial studies the side effects and best dose of berzosertib (M6620) when given together with cisplatin and radiation therapy in treating patients with head and neck squamous cell carcinoma that has spread from where it started to nearby tissue or lymph nodes (locally advanced). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving M6620 together with cisplatin and radiation therapy may work better in treating patients with locally advanced head and neck squamous cell carcinoma.

調査の概要

状態

積極的、募集していない

介入・治療

詳細な説明

PRIMARY OBJECTIVES:

I. Assess the safety and tolerability of M6620 (VX-970, berzosertib) when administered along with weekly cisplatin and radiation therapy (XRT) in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).

II. Establish the recommended phase 2 dose (RP2D) of the combination.

SECONDARY OBJECTIVES:

I. Characterize the pharmacokinetic (PK) profile of M6620 (VX-970, berzosertib).

II. Assess for potential drug-drug interaction between M6620 (VX-970, berzosertib) and aprepitant.

III. To observe and record anti-tumor activity. IV. To assess the rate of complete metabolic response (CMR) at 12 weeks post completion of chemoradiation using 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) scans.

V. To collect archival tumor material for retrospective analysis of association between tissue-based biomarkers and clinical outcome.

OUTLINE: This is a dose-escalation study of berzosertib.

Patients receive berzosertib intravenously (IV) over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo computed tomography (CT), PET/CT, or magnetic resonance imaging (MRI) throughout the study.

After completion of study treatment, patients are followed up for 30 days, every 2 weeks for 3 months, and then every 3 months for 2 years.

研究の種類

介入

入学 (実際)

43

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • City of Hope Comprehensive Cancer Center
      • Sacramento、California、アメリカ、95817
        • University of California Davis Comprehensive Cancer Center
    • Connecticut
      • New Haven、Connecticut、アメリカ、06520
        • Yale University
      • New Haven、Connecticut、アメリカ、06510
        • Smilow Cancer Center/Yale-New Haven Hospital
      • Trumbull、Connecticut、アメリカ、06611
        • Smilow Cancer Hospital Care Center-Trumbull
    • Georgia
      • Atlanta、Georgia、アメリカ、30308
        • Emory University Hospital Midtown
      • Atlanta、Georgia、アメリカ、30322
        • Emory University Hospital/Winship Cancer Institute
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • University of Iowa/Holden Comprehensive Cancer Center
    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • University of Kentucky/Markey Cancer Center
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore、Maryland、アメリカ、21201
        • University of Maryland/Greenebaum Cancer Center
    • Michigan
      • Detroit、Michigan、アメリカ、48201
        • Wayne State University/Karmanos Cancer Institute
    • New Hampshire
      • Lebanon、New Hampshire、アメリカ、03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    • New Jersey
      • New Brunswick、New Jersey、アメリカ、08903
        • Rutgers Cancer Institute of New Jersey
    • Ohio
      • Cleveland、Ohio、アメリカ、44106
        • Case Western Reserve University
      • Columbus、Ohio、アメリカ、43210
        • Ohio State University Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • UPMC Hillman Cancer Center
    • Virginia
      • Charlottesville、Virginia、アメリカ、22908
        • University of Virginia Cancer Center
    • Wisconsin
      • Madison、Wisconsin、アメリカ、53792
        • University of Wisconsin Carbone Cancer Center - University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed head and neck squamous cell cancer (HNSCC) including paranasal sinus cancers but excluding nasopharyngeal carcinomas
  • Clinical staged III or IV HNSCC, according to American Joint Committee on Cancer (AJCC) 7th Edition, that is not amenable to surgical resection
  • Carcinoma of the neck of unknown primary site origin (regardless of HPV/p16 status) is eligible
  • Age >= 18 years; because no dosing or adverse event data are currently available on the use of M6620 (VX-970, berzosertib) in combination with cisplatin in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Life expectancy of greater than 3 months
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
  • Leukocytes >= 3,000/mcL
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin within normal institutional limits
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
  • Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
  • The effects of M6620 (VX-970, berzosertib) on the developing human fetus are unknown; for this reason and because DNA-damage response (DDR) inhibitors as well as other therapeutic agents used in this trial may have teratogenic potential, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of M6620 (VX-970, berzosertib) administration
  • Ability to understand and the willingness to sign a written informed consent document
  • Women of childbearing potential who are sexually active should be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for up to 6 months following the last administration of study treatment; men who are sexually active must be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for 6 months after completion of M6620 (VX-970, berzosertib) administration

Exclusion Criteria:

  • Patients with nasopharyngeal carcinoma, skin squamous cell carcinoma (SCC), and salivary gland carcinomas are not eligible

  • Patients who are receiving adjuvant chemoradiation after surgical resection of the primary site of disease

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier

  • Patients who are receiving any other investigational agents

  • Patients on tacrolimus or any other immunosuppressants with significant interaction with cisplatin

  • Patient who requires live vaccine administration

  • Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970, berzosertib) or cisplatin

  • Prior systemic chemotherapy for the current cancer (prior chemotherapy for a different cancer is allowed)

  • Prior receipt of radiotherapy that would result in overlap of the new and old radiation therapy fields

  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation
    • Symptomatic congestive heart failure (requiring hospital stay within the last 6 months)
    • Myocardial infarction within the last 6 months
    • Unstable angina pectoris, cardiac arrhythmia
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because M6620 (VX-970, berzosertib) as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M6620 (VX-970, berzosertib), breastfeeding should be discontinued if the mother is treated with M6620 (VX-970, berzosertib); these potential risks may also apply to other agents used in this study

  • Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible because of the potential for pharmacokinetic interactions; patients with poorly controlled HIV are not eligible due to the increased risk of lethal infections when treated with marrow-suppressive therapy

  • Definitive clinical or radiographic evidence of distant metastasis or adenopathy below the clavicles

  • M6620 (VX-970, berzosertib) is primarily metabolized by CYP3A4; therefore, concomitant administration with strong inhibitors or inducers of CYP3A4 should be avoided; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (berzosertib, cisplatin, radiation therapy)

Patients receive berzosertib IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT, or MRI throughout the study.

Correlative studies

Given IV

他の名前:
  • CDDP
  • シスジアミンジクロリド白金
  • シスマプラット
  • シスプラチナム
  • ネオプラチン
  • プラチノール
  • アビプラチン
  • ブラストレム
  • ブリプラチン
  • シス-ジアミン-ジクロロ白金
  • シス-ジアミンジクロロ 白金(II)
  • シスジアミンジクロロ白金
  • Cis-ジクロロアミン プラチナ (II)
  • シス白金ジアミンジクロリド
  • シスプラチナ
  • シスプラチナⅡ
  • シスプラチナⅡジアミンジクロリド
  • シスプラチル
  • シトプラチノ
  • シトシン
  • シスプラティナ
  • DDP
  • レーダープラチン
  • メタプラチン
  • ペイロンの塩化物
  • ペロンの塩
  • プラシス
  • プラススティル
  • プラタミン
  • プラチブラスチン
  • プラチブラスチン-S
  • プラティネックス
  • プラチノール-AQ
  • プラチノール-AQ VHA プラス
  • プラチノキサン
  • 白金
  • 白金ジアミノ二塩化物
  • プラティラン
  • プラティスチン
  • プラトシン

Undergo MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Undergo CT or PET/CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Undergo PET/CT

他の名前:
  • 医用画像、陽電子放出断層撮影
  • ペット
  • PETスキャン
  • 陽電子放出断層撮影スキャン
  • 陽電子放出断層撮影
  • PT
  • 陽電子放出断層撮影(手順)

Given IV

他の名前:
  • 2-ピラジナミン、3-(3-(4-((メチルアミノ)メチル)フェニル)-5-イソキサゾリル)-5-(4-((1-メチルエチル)スルホニル)フェニル)-
  • M 6620
  • M6620
  • VX970
  • VX-970

Undergo radiation therapy

他の名前:
  • がん放射線治療
  • ENERGY_TYPE
  • 照射する
  • 照射された
  • 照射
  • 放射線
  • 放射線治療、NOS
  • 放射線治療学
  • 放射線治療
  • RT
  • 治療、放射線
  • エネルギーの種類

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants Experiencing Grade 3, 4, and 5 Adverse Events
時間枠:Up to 6.5 years

According to the Cancer Therapy Evaluation Program National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v. 5). The highest grade experienced by the participant will be reported.

Up to 6.5 years
Number of Participants Experiencing a Dose Limiting Toxicities
時間枠:Up to 3 weeks after completion of radiation therapy

Dose limiting toxicities are protocol-specific adverse events considered at least possibly related to the study intervention. Graded according to NCI CTCAE v5.

Up to 3 weeks after completion of radiation therapy
Establish the Recommended Phase 2 Dose (RP2D)
時間枠:Up to 7 weeks

Defined as the highest doses of cisplatin and berzosertib safely combined with radiation.

Up to 7 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Pharmacokinetic Characteristics of Berzosertib
時間枠:Up to Day 5

The maximum concentration ratio between Day -7 collections to Day 2 collections. Collection time points are baseline, 30 and 55 minutes after the start of M6620 infusion, 5, 15, 30 minutes, 1, 2, 4, 23 (Day 3), 48 (Day 4), and 72 hours (Day 5) after the end of M6620 infusion given on Day 2.

Up to Day 5
Potential Drug-drug Interaction
時間枠:Up to Day 5

The maximum concentration of M6620 in the blood when aprepitant is also given.

Up to Day 5
Number of Participants Experiencing a Response
時間枠:Up to 6.5 years

Evaluated by Response Evaluation Criteria in Solid Tumors 1.1. Response is defined as complete response (disappearance of all target and non-target lesions) or partial response (at least a 30% decrease in the sum of diameters of target lesions from baseline).

Up to 6.5 years
Number of Participants Experiencing a Metabolic Response
時間枠:At week 12 after completing intervention

Assessed by fluorodeoxyglucose-positron emission tomography (FDG PET) and measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Metabolic response are participants demonstrating a complete response (disappearance of all target and non-target lesions) or a partial response (at least a 30% decrease in the sum of diameters of target lesions from baseline).

At week 12 after completing intervention
Expression of Tissue-based Biomarkers as Markers of Deoxyribonucleic Acid Damage and Predictors of Clinical Outcome
時間枠:Up to 6.5 years

Kaplan-Meier curves for Progression Free Survival (PFS), defined as time to disease progression, and Overall Survival (OS), defined as time until death or off study, were used to evaluate if the gene expression profiles of ERCC1 and XRCC1, and TP53 correlated to these outcomes.

Up to 6.5 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Taofeek K Owonikoko、JHU Sidney Kimmel Comprehensive Cancer Center LAO

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年4月17日

一次修了 (実際)

2023年12月31日

研究の完了 (推定)

2027年5月14日

試験登録日

最初に提出

2015年10月2日

QC基準を満たした最初の提出物

2015年10月2日

最初の投稿 (推定)

2015年10月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月14日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCI-2015-01643
  • UM1CA186691 (米国 NIH グラント/契約)
  • UM1CA186690 (米国 NIH グラント/契約)
  • N01CM00100 (米国 NIH グラント/契約)
  • NCI-2015-01643 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • 9950 (その他の識別子:CTEP)
  • 9950 (その他の識別子:JHU Sidney Kimmel Comprehensive Cancer Center LAO)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。